Objectively measure speech in Parkinson’s disease patients with great precision

In 2020, an estimated 9.4 million people globally were living with Parkinson’s disease, with numbers increasing to 12.7 million people by 2027. Coupled with the subjective nature of current Parkinson’s disease monitoring assessment methods, there is a need for sensitive, scalable and meaningful assessments of disease monitoring. Redenlab is a world leader in the development of speech data capture and analysis tools, creating objective motor speech and cognitive-linguistic -based assessments. Their approach has proven utility in industry and academic driven studies, enhancing decision making at each stage of the drug development and evaluation process.

ParkinSong: a clinical trial turn PD treatment

Working with scientists from the Conservatorium of Music at The University of Melbourne in Australia, Redenlab assisted in outcome measure design and analysis for a randomized trial of ParkinSong, a group therapy session for people with Parkinson’s disease.

Since it’s clinical trial, the therapy has been employed across Australia by Parkinson’s Australia, an Australian advocacy group dedicated to improving the quality of life of people diagnosed with Parkinson’s disease.

Redenlab Parkinson’s Disease experience








Clinical trials



Natural history studies


Latest news and updates

  • Posted on 17 October, 2021

    Redenlab’s latest iOS application provides state of the art audio capture, storage and analysis of speech and language data for monitoring brain health.

    • Posted on 27 September, 2021

      Dr Amir Lahav hired as Chief of Digital Health and Strategy. He is a clinical neuroscientist and a leading innovator in digital health with a special focus on developing and validating novel biomarkers and AI-driven technology for remote monitoring of patients with neurodegenerative diseases.